Navigation Links
Phase I trial begins using gene therapy and bone marrow stem cells in the treatment of brain cancer
Date:11/14/2011

Cleveland, OH. and Gaithersburg, MD. University Hospitals (UH) Case Medical Center, Case Western Reserve University School of Medicine and Lentigen Corporation announced today the initiation of a novel Phase I clinical trial of LG631 gene therapy for the protection of hematopoietic stem cells (HSCs) from the dose limiting toxicity of chemotherapy with Temodar.

Approximately 17,000 Americans are diagnosed with glioblastoma every year and only two percent of them survive longer than five years even with aggressive treatment. Glioblastoma (GBM) treatment generally begins with a surgical resection, followed by radiation therapy and then chemotherapy to destroy any remaining cancer cells. Temodar (temozolomide, Merck and Co., Inc.) is a standard treatment of glioblastoma, but dose-limiting bone marrow toxicity often accompanies such therapy.

In this first-of-its-kind study, researchers are investigating if LG631 can potentially improve tolerance and effectiveness of chemotherapy for GBM by preventing damage to bone marrow. The study will evaluate the safety of this treatment and its potential to enhance current GBM treatments.

For this study, HSCs will be isolated from participating patients, transduced with LG631, an altered human-Methylguanine Methyltransferase (MGMT) gene to make them resistant to Temodar, and then infused back into the patient. The MGMT gene has been shown to repair damaged DNA. The specially designed Lentiviral vector (LG631) will be used to deliver the gene specifically to bone marrow stem cells that are susceptible to damage by drugs commonly used to treat cancer, thereby enabling patients to receive higher doses of Temodar with less severe side effects.

"Glioblastoma is a devastating disease and many patients do not benefit from standard therapy," notes Dr. Andrew Sloan, Director of the Brain Tumor and Neuro-Oncology Center, UH Case Medical Center and Associate Professor of Neurological Surgery and
'/>"/>

Contact: Alicia Reale
alicia.reale@uhhospitals.org
216-844-5156
University Hospitals Case Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Phase III data show efficacy/safety of iclaprim in patients with complicated skin infections
2. Positive results in Phase 2 trial of treatment of C-difficile-associated diarrhea
3. NIH grants Phylonix Phase II SBIR to develop high-throughput in vivo zebrafish assays
4. Biolex presents Locteron US Phase 2a hepatitis C data at EASL
5. Cantabrian cornice has experienced seven cooling and warming phases over past 41,000 years
6. Resolvyx announces positive data -- Phase 2 trial of resolvin RX-10045 for dry eye syndrome
7. Scientists seek new emphases in Arctic climate change research
8. NIH funds new phase of high school-university research partnership
9. Registration Opens for Next Testing Phase of IEEE Certified Biometrics Professional Program
10. First phase of pan-tropical forest mapping debuting at COP15
11. ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human])
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... -- C-Labs LLC, a leading provider of remote and ... announced the appointment of John Traynor to ... advisor to the firm, Mr. Traynor will now oversee ... out of the C-Labs office in Redmond, ... , Chief Executive Officer. Photo - ...
(Date:11/18/2014)... , Nov. 17, 2014   ... and EMC collaborate to develop The Partners Data ... , The Partners Data Lake will allow researcher ... improve diagnostics, treatment and the lives of patients ... research and clinical activities across the Partners system, ...
(Date:11/15/2014)... 2014  While we may still be a few years ... "Star Trek" to gain instant access to all that ailed ... smartphones and tablets for monitoring and measuring our health are ... may seem a tad Orwellian to some, but a new ... these technological opportunities into their healthcare regime. These ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... at the Kimmel Cancer Center at Jefferson (KCC) (insert ... developed potentially game-changing diagnostic and prognostic genetic tests shown ... clinically-relevant cancers. The team, led by ... the KCC and the Chair of the Department ...
... a $480,000 gift from the Emily Landecker Foundation. The ... Astrobiology, which will support graduate students in the School ... astrobiology. The fellowship is named in honor of Ferris, ... a senior research professor, and a member of the ...
... of two University of California, Berkeley, scientists who are part ... complete genome sequence. "This genome has revolutionized our studies," ... cell biology who lobbied for inclusion of the leech in ... animals in order to learn what they have in common ...
Cached Biology News:Game changing diagnostic & prognostic prostate cancer genetic tests revealed by Jefferson 2Game changing diagnostic & prognostic prostate cancer genetic tests revealed by Jefferson 3Rensselaer awarded gift to establish fellowship in astrobiology 2What do leeches, limpets and worms have in common? Now, a sequenced genome 2What do leeches, limpets and worms have in common? Now, a sequenced genome 3
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
(Date:12/17/2014)... 2014 Audacity, a leading California-based health ... of the Huntsworth Health Group, is proud to announce ... In her role, Gonzales will serve as Senior Vice ... honored to welcome a talent of Jamie’s caliber to ... Fraikin. “She is a proven healthcare innovation leader and ...
(Date:12/17/2014)... Dec. 17, 2014   Synageva BioPharma Corp. ... therapeutic products for rare disorders, announced today its presentation ... in San Francisco, CA. ... Executive Officer, will present on Monday, January 12, 2015, ... will be webcast live and may be accessed from ...
(Date:12/15/2014)... Agritech Limited (NASDAQ GS: SEED) (" Origin ", or the ... China , today announced that the Company ... 30, 2014, before the market opens on Thursday, January 8, ... January 8, 2015, at 8:00 a.m. ET / 9:00 p.m. ... To participate in the call, please dial +1-888-346-8982 in ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3
... CALGARY, June 4 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc.,(TSX:SBS), ... for metabolic and cardiovascular diseases, today announced that,Andrew ... present a corporate,update at the Needham & Company, ... presentation is scheduled on Wednesday,June 11 at 2:30 ...
... In a plan designed to develop,educational opportunities ... Tiger Woods Learning Center (TWLC) are collaborating to ... report by the National,Research Council studied the declining ... likely to have increased scientific interests if they ...
... Medical Corporation,(OTC Bulletin Board: CONX), a worldwide developer ... AspirinWorks(R) Test at the,American Diabetes Association,s 68th Scientific ... 7 - 9, 2008, at the Moscone Convention,Center ... first time the AspirinWorks test will be exhibited ...
Cached Biology Technology:LI-COR(R) Biosciences and Tiger Woods Learning Center Collaborate to Develop High School Curriculum in Genetics 2Corgenix to Exhibit AspirinWorks(R) Test at ADA 2008 Meeting in San Francisco 2Corgenix to Exhibit AspirinWorks(R) Test at ADA 2008 Meeting in San Francisco 3
... biomarker discovery projects require screening through ... distinguish clinically relevant data from normal ... Manager is now available to help ... and data flood inherent to biomarker ...
This free-standing laminar flow hood provides a vertical flow of HEPA-filtered air to create a clean processing area. It includes a fluorescent light and motorized sliding shield. Options include wor...
This modular laminar flow hood forces air through a 99.99% efficient HEPA filter to create a clean processing area. Configurations are available with vertical or horizontal flow; options include a wo...
... provider of X-ray crystallography services for ... services to its pharmaceutical and biotechnology ... of drug-like fragments to the active ... allowing scientists to develop novel, high-affinity ...
Biology Products: